# Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/recommended-followup-testing-for-an-ames-positive-drug-active-ingredient-or-metabolite-to-support-first-in-human-clinical-trials-with-healthy-subjects/ce4cb94e-e7a9-4c9d-a289-a55bc94e74c1

> FDA guidance document: Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects. Issue date: November 27, 2024. Get complete insights and analysis.

---

## Details

- Title: Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-11-27
- Comment Close Date: 2025-02-25
- Last Changed: 2024-11-27
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-4540">FDA-2024-D-4540</a>

## Related Documents

- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/meta-analyses-of-randomized-controlled-clinical-trials-to-evaluate-the-safety-of-human-drugs-or-biological-products/0ed49ff3-89c9-4436-8c06-0324d3e2aff2)
- [Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials](https://www.globalkeysolutions.net/guidances/guidance-document/pregnant-women-scientific-and-ethical-considerations-for-inclusion-in-clinical-trials/674ff9d8-e752-4113-b7fd-bc85b7646bd3)